Niki BioSolutions, Inc. has announced the appointment of Ian Huen as Chief Executive Officer and Alidad Mireskandari as President and Chief Operating Officer, effective August 1, 2026. The appointments were formalized through separate agreements signed on September 1, 2026.
Under the terms of the appointment letter for Mr. Huen, he will serve as CEO with an initial term of six months, subject to renewal by mutual agreement. His monthly base salary is set at HKD 210,000, which converts to approximately USD 26,800 based on an exchange rate of 7.84. He is also eligible for a discretionary bonus determined by the Board and Compensation Committee, as well as share bonuses and options to purchase shares under the company's Share Option Plan. The agreement allows for termination with one month's prior written notice, or immediate termination under specified circumstances.
Mr. Mireskandari’s employment agreement details a base salary of $320,000 per year. A portion of this salary, $35,000, is deferred until the company receives capital investment proceeds of $3,000,000. If the company secures aggregate capital investments totaling $5,000,000 during his tenure, his base salary will increase to $350,000. Additionally, he is eligible for an annual performance bonus of up to 50% of his base salary. Upon the closing of the merger transaction, he was granted 20,000 restricted stock units (RSUs) and options to purchase 800,000 shares of common stock under the 2026 Equity Incentive Plan.
